首页> 外文期刊>The Canadian journal of hospital pharmacy. >Should Azithromycin No Longer Be Considered a Drug of Choice for Community-Acquired Pneumonia Because of Its Potential to Cause Cardiovascular Death?
【24h】

Should Azithromycin No Longer Be Considered a Drug of Choice for Community-Acquired Pneumonia Because of Its Potential to Cause Cardiovascular Death?

机译:阿奇霉素是否有可能导致心血管死亡,因此不再应被视为社区获得性肺炎的首选药物吗?

获取原文
获取原文并翻译 | 示例
           

摘要

The current Canadian and US guidelines for community-acquired pneumonia (CAP) recommend azithromycin alone in mild cases and azithromycin in combination with a beta-lactam for patients admitted to hospital with moderate to severe CAP. To demonstrate that azithromycin should not be considered an alternative for the treatment of CAP, a medication assessment-based on indication, effectiveness, and safety-will be completed.
机译:加拿大和美国目前针对社区获得性肺炎(CAP)的指南建议,中度至重度CAP住院的患者在轻度病例中应单独使用阿奇霉素,与β-内酰胺联合使用阿奇霉素。为了证明不应该将阿奇霉素视为治疗CAP的替代药物,将完成基于适应症,有效性和安全性的药物评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号